A Novel Nomogram for Individually Predicting of Vascular Invasion in Gastric Cancer

Technol Cancer Res Treat. 2021 Jan-Dec:20:15330338211004924. doi: 10.1177/15330338211004924.

Abstract

Purpose: Vascular invasion (VI) is associated with recurrence and is an indicator of poor prognosis in gastric cancer (GC). Pre-operative identification of VI may guide the selection of the optimal surgical approach and assess the requirement for neoadjuvant therapy.

Methods: A total of 271 patients were retrospectively collected and randomly allocated into the training and validation datasets. The least absolute shrinkage and selection operator regression model was used to select potentially relevant features, and multivariable logistic regression analysis was used to develop the nomogram.

Results: The nomogram consisted of pre-operative serum complement C3 levels, duration of symptoms, pre-operative computed tomography stage, abdominal distension and undifferentiated carcinoma. The nomogram provided good calibration for both the training and the validation set, with area under the curve values of 0.792 and 0.774. Decision curve analysis revealed that the nomogram was clinically useful.

Conclusion: The present study constructed a nomogram for the pre-operative prediction of VI in patients with GC. The nomogram may aid the identification of high-risk patients and aid the optimization of pre-operative decision-making.

Keywords: complement C3; gastric cancer; nomogram; selection operator; the least absolute shrinkage; vascular invasion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / blood*
  • Complement C3 / analysis*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neovascularization, Pathologic / blood
  • Neovascularization, Pathologic / pathology*
  • Nomograms*
  • Prognosis
  • Retrospective Studies
  • Stomach Neoplasms / blood
  • Stomach Neoplasms / blood supply
  • Stomach Neoplasms / pathology*

Substances

  • Biomarkers, Tumor
  • Complement C3